Incyte announced Sept. 22 that the Food and Drug Administration approved the company’s Jakafi (ruxolitinib) to treat chronic graft-versus-host disease, one day after the U.S. regulator gave the green light to the cream Opzelura (ruxolinitib) for the short-term and non-continuous chronic treatment of mild-to-moderate atopic dermatitis.
If you are not happy with the results below please do another search
50 search results for:
U.K.-based Monument Therapeutics hopes to overcome limitations of treatments for schizophrenia drugs with a study of the company’s proprietary non-invasive biomarker for cognitive impairment.
The U.S. Food and Drug Administration on Sept. 22 authorized a booster dose of the Pfizer Inc. and BioNTech Covid-19 vaccine for those 65 and older, all people at high risk of severe disease, and others who are regularly exposed to the virus.
French vaccine maker Valneva is expanding trials of a Covid-19 vaccine candidate called VLA2001, and remains in talks with the European Commission over a potential contract, the company said on Sept. 23.
AstraZeneca on Sept. 23 struck a deal with the firm behind Imperial College London’s experimental Covid-19 vaccine to develop and sell drugs based on VaxEquity’s self-amplifying RNA technology platform in other disease areas.
Matthew Howes was appointed Chief Strategy Officer at The Greater Than One Group (GTO), a privately held, global marketing and communications agency with a proprietary model and focused approach leveraging data, content and media.
Severe Covid-19 may trick the immune system into producing so-called autoantibodies that have the potential to eventually attack healthy tissue and cause inflammatory diseases, researchers warned in a paper published in Nature Communications. Another study suggests that the virus that causes Covid-19 may be getting better at traveling into the air
Monoclonal antibodies are playing a key therapeutic role in the treatment of some Covid-19 patients, but new research suggests that nanobodies derived from llamas could provide an alternative to monoclonal antibodies through a more effective delivery method—inhalation.
Fishawack Health, a leading commercialization partner for the life science industry, appointed Elizabeth (Liz) Landon to a newly created executive role as Chief People Officer.
Why aren’t more people getting vaccinated? The answer comes down to a lack of trust, according to the COVID States Project, the largest ongoing national survey tracking people’s opinions and behaviors during the pandemic.